Document:

ex1078053rdamendpsasw.htm

EX-10.78.05

 

 

AMENDMENT NO. 3 TO AGREEMENT OF PURCHASE, SALE AND CONTRIBUTION

This is Amendment No. 3 dated as of July 13, 2010 (this “Third Amendment”) to that certain Agreement of Purchase, Sale and Contribution, entered into on January 15, 2010 (the “Original PSA”) by and between Stayton SW Assisted Living, L.L.C. ("Stayton"), an Oregon limited liability company constituting the Unitary Sunwest Enterprise designated in the Approval Order of the United States District Court for the District of Oregon dated October 2, 2009, and BRE/SW Portfolio LLC, a Delaware limited liability company (hereinafter referred to as "Purchaser"), as amended by that certain Amendment No. 1 to Agreement of Purchase, Sale and Contribution dated February 12, 2010 (the “First Amendment”) and Amendment No. 2 to Agreement of Purchase, Sale and Contribution dated March 25, 2010 (the “Second Amendment”).  The Original PSA, as amended by the First Amendment and the Second Amendment shall be referred to herein as the "PSA".

For good and valuable consideration, receipt and sufficiency of which are hereby acknowledged, the parties, intending to be legally bound hereby, agree as follows:

1. Amendments to PSA:  Stayton and Purchaser agree that the PSA shall be amended as follows:

 

       a) (i)           Section 1.1 of the PSA is amended by adding the following additional defined terms:

“Confirmation Order” means an order of the Court, reasonably satisfactory in form and substance to Purchaser, Stayton and their respective counsel, entered after a hearing conducted with adequate notice given, (a) confirming the Reorganization Plan and (b) satisfying the requirements of the definition “Sale Approval Order”.

“Excess Common Rollover Amount” shall have the meaning set forth in Section 2.6(d)(ii).

“Excess Preferred Rollover Amount” shall have the meaning set forth in Section 2.6(d)(ii).

“Excess Rollover TEC Adjustment” shall have the meaning set forth in Section 2.6(d)(iii).

“Final Adjustment Date” shall have the meaning set forth in Section 8.5(p)(i).

“Final Common Rollover Amount” shall have the meaning set forth in Section 2.6(d)(ii).

“Final Preferred Rollover Amount” shall have the meaning set forth in

  

Page 1

  

Section 2.6(d)(ii).

“Final Rollover Certificate” shall have the meaning set forth in Section 2.6(d)(ii).

“Final Total Equity Capitalization” shall have the meaning set forth in Section 2.6(d)(iii).

“Unliquidated Secured Claims” means with respect to the Assumed Real Property Loans, those certain amounts agreed to between Stayton and the applicable lenders under such Assumed Real Property Loans and specifically reflected on the closing statement delivered pursuant to Sections 8.3(t) and 8.4(f) as “Potential Unliquidated Secured Claims”, which relate to lender fees, legal fees, other capitalized expenses and other adjustments to principal included in the outstanding principal amount of the Actual Assumed Real Property Loan Balance as of the Closing Date, but which are subject to the approval of the Court.

“Unliquidated Secured Claim Adjustment” shall mean the amount by which the Actual Assumed Real Property Loan Balance is conclusively and effectively reduced after the Closing Date solely as a result of a final Order of the Court reducing the amounts payable with respect to the Unliquidated Secured Claims, provided, however, the “Unliquidated Secured Claim Adjustment” shall not include any reduction amounts relating to amounts which are thereafter imposed or charged to Purchaser in connection with or arising out of such principal reduction.

 

       b) Section 1.1 of the PSA is amended by deleting the definitions “Effective Date” and “Salem HQ Lease” and replacing each in its entirety with the following, as applicable:

“Effective Date” means the date which is thirty one (31) days following the date on which the Confirmation Order is entered into, without being subject to a stay.

“Salem HQ Lease” means a sublease between Stayton as sublandlord and Purchaser’s manager as subtenant of a portion of the office space currently occupied by Stayton at 3727 Fairview Industrial Drive, Salem, Oregon, on a form customary or similar space in Oregon having the following terms: (i) a lease term of six (6) months, (ii) a monthly rent of $21,000, (iii) a demised premises with (A) a square footage as may be designated by Purchaser’s Manager, provided that such premises shall not exceed 50% of the space occupied by Stayton as of the date hereof and (B) a configuration reasonably acceptable to Purchaser’s Manager.

  

Page 2

  

 

       c) Section 2.6(c)(iii) of the PSA is amended by adding the following sentence at the end of such Section:

“The foregoing initial Common Percentages of the Members and the Total Equity Capitalization are subject to adjustment at the Final Adjustment Date pursuant to Section 2.6(d), which adjustment shall be effective under the Blackstone Venture LLC Agreement retroactively as of the Initial Closing Date.”

 

       d) Section 2.6(d) of the PSA is replaced in its entirety by the following:

“(d)

 

(i)        At or prior to Closing, Stayton shall deliver to Purchaser (A) a preliminary list, by Property, of the Allowed Claims (as defined in the Distribution Plan) for each Investor that participates in the Rollover Equity Election, which list shall be attached to the Blackstone Venture LLC Agreement as Schedule 4.6A-2, as certified by Stayton and the Receiver and (B) a list of all Rollover Investors and their estimated membership interests in the Rollover Member, as certified by Stayton and the Receiver.

 

(ii)        Upon the earlier to occur of (A) the completion of the Claims Process (as defined in the Distribution Plan) and (B) December 31, 2010, the Receiver shall deliver to Purchaser the Final Rollover Certificate.  The “Final Rollover Certificate” shall include the following information, in each case as of a date not later than November 30, 2010, and shall be certified as true, correct and complete by Stayton, the Receiver and the Rollover Member: (x) an updated and final list, by Property, of Allowed Claims for each Investor that participates in the Rollover Equity Election, which updated list shall be deemed to update Schedule 4.6A-2 of the Blackstone Venture LLC Agreement, (y) an updated list of all Rollover Investors and their final membership interest in the Rollover Member, and (z) an updated and final calculation of the Preferred Rollover Amount (the “Final Preferred Rollover Amount”) and the Common Rollover Amount (the “Final Common Rollover Amount”) resulting from the Claims Process, which amounts shall not be greater than the Preferred Rollover Amount and the Common Rollover Amount at Closing, respectively.  In the event that the Preferred Rollover Amount at the Closing exceeds the Final Preferred Rollover Amount (such excess, the “Excess Preferred Rollover Amount”) or the Common Rollover Amount at the Closing exceeds the Final Common Rollover Amount (such excess, the “Excess Common Rollover Amount”), (1) the Common Percentages of the Common Members (as such term is defined in the Blackstone Venture LLC

 

  

Page 3

  

Agreement) shall be adjusted and the Class A Preferred Units of the Rollover Member shall be reduced, as applicable in accordance with Section 11.20 of the Blackstone Venture LLC Agreement and effective retroactively as of the Initial Closing Date and (2) Purchaser shall pay to Stayton within ten Business Days following delivery to Purchaser of the Final Rollover Certificate, an amount equal to the Excess Preferred Rollover Amount and the Excess Common Rollover Amount; provided that Purchaser receives a certificate executed by Rollover Member containing the information called for by Section 11.20 of the Blackstone Venture LLC Agreement.

 

(iii)        In the event that Purchaser elects not to acquire one or more Deferred Properties pursuant to Section 8.6(c), and as a result, Purchaser determines that the Final Common Rollover Amount is greater than 49% of the Total Equity Capitalization as finally determined by Purchaser and taking any such elections into account (the “Final Total Equity Capitalization”), then Purchaser shall have the right, on or before the Final Adjustment Date, to adjust the Common Percentages of the Common Members effective retroactively as of the Initial Closing Date such that the Common Percentage of the Rollover Member equals 49% (as such percentage may be adjusted to reflect any other changes to the Common Percentages which may have occurred in accordance with the Blackstone Venture LLC Agreement prior to the Final Adjustment Date) and upon such adjustment, Purchaser shall be required to pay to Stayton on the Final Adjustment Date in accordance with Section 8.5(p), an amount equal to (x) the Final Common Rollover Amount less (y) 49% of the Final Total Equity Capitalization (the “Excess Rollover TEC Adjustment”).

 

(iv)        In the event that prior to the Final Adjustment Date, the Unliquidated Secured Claims are reduced pursuant to a final Order of the Court, a copy of which is delivered to Purchaser, Purchaser shall be required to pay to Stayton on the Final Adjustment Date in accordance with Section 8.5(p), an amount equal to the Unliquidated Secured Claims Adjustment.”

	
e) 

	
Section 5.1(d) is amended by deleting the words “Purchaser's prior written approval” in the line 14 thereof and replacing them with the words “Purchaser's specific written approval.”

	
f) 

	
Section 7.1(f) is deleted in its entirety and replaced with the following:

“(f)           The Effective Date shall have occurred.”

 

	
g) 

	
Section 7.1(n)(v) is amended by replacing the words “creditor’s rights exclusion

  

Page 4

  

deletion” with the word “[reserved]”.

	
h)  

	
The following is added as a new Section 7.1(o):

“(o)         all of the conditions precedent required by any lender in connection with the assumption by the Acquiring Entities of each Assumed Real Property Loan or Assumed Personal Property Loan shall have been satisfied.”

	
i)  

	
Section 8.4 of the PSA is amended by adding the following new subsection 8.4(j):

“(j)           the Salem HQ Lease executed by Purchaser's Manager as subtenant, provided, however, that Purchaser’s Manager shall not be required to execute and deliver the Salem HQ Lease unless Stayton and Purchaser’s Manager enter into a license agreement or cost-sharing agreement reasonably acceptable to Purchaser’s Manager with respect to Stayton’s continued use of any portion of the subleased premises.”]

 

	
j)  

	
Section 8.5(p) is deleted in its entirety and replaced with the following:

“(p)           Post Closing Final Adjustment.

 

                     

	
  

	
(i)

	
If any errors or omissions in computing the apportionments under Section 8.5 shall be discovered, Stayton and Purchaser shall promptly make appropriate adjusting payments to each other to correct such errors or omissions.  All amounts owing from or to Stayton, or from or to Purchaser, that require adjustment after the Closing Date shall be settled within 120 days after the final Closing Date under the PSA (the “Final Adjustment Date”).  Purchaser and Stayton shall each make such records available for inspection by the other party as are reasonable to demonstrate the accuracy of any adjustments.

 

	
  

	
(ii)

	
In addition to any adjustments made on the Final Adjustment Date pursuant to clause (i) of this Section 8.5(p), unless theretofore paid in full, Purchaser shall pay to Stayton, (A) the Excess Preferred Rollover Amount and the Excess Common Rollover Amount, if applicable pursuant to Section 2.6(d)(ii), (B) the Excess Rollover TEC Adjustment, if applicable pursuant to Section 2.6(d)(iii) and (C) the Unliquidated Claim Adjustment, if applicable pursuant to Section 2.6(d)(iv).

 

	
  

	
(iii)

	
In connection with determining the amount of adjustments payable on the Final Adjustment Date under this Section 8.5(p), all such amounts shall be aggregated together and the party responsible for the net payment as a result of such adjustments shall make such payment within two (2) business days of the Final Adjustment Date.

 

  

Page 5

  

	
k)  

	
Section 9.2(c) is amended by deleting the words “Corporate Employees” in the second line thereof and replacing them with the words “Designated Corporate Employees”.

	
l)  

	
Sections 12.1 (c) of the PSA is deleted in its entirety

	
m)  

	
Section 12.1 (d) of the PSA is amended in its entirety to read as follows:

"12.1                              Termination

 

Subject to Section 8.6, Article 11 and Article 13 and, with respect to any termination by Stayton, subject to approval of the Court, this Agreement may be terminated in its entirety, or, in the limited circumstances provided herein, as to some, but not all of the Properties, prior to the Closing only:

 

*                   *                      *                      *                      *

 

(d)           by Stayton or Purchaser if the Closing has not occurred on or before November 30, 2010 (the “Outside Closing Date”);"

 

	
2.  

	
Amendments to Exhibits.

 

       a) The Allocated Purchase Price schedule attached to the PSA as Exhibit A-2 shall be amended by deleting such exhibit in its entirety and substituting therefor Exhibit A-2 attached to this Amendment.

 

       b) The list of Required Removal Exceptions attached to the PSA as Exhibit M-3 shall be amended by deleting in their entirety the following exceptions:

	
(i)  

	
Big Sky (MT) Exception #17 – Property Owners Association Agreement (table of Missing Title Documents);

	
(ii)  

	
Montclair Park (WA) Exception #10 – Use Limitations and Declaration of Restricted Covenants recorded on 5/22/02, as amended by Amended and Restated Use Limitation and Declaration of Restricted Covenants recorded on 1/22/03; and

	
(iii)  

	
River Road (OR) Exception #18 – Regulatory Agreement and Declaration of Restrictive Covenants, dated 11/25/98, between Jilar Keizer Enterprises, L.L.C. and the Oregon Housing and Community Services Department, and recorded on 12/1/98.

 

       c) The list of Required Title Consent Properties attached to the PSA as Exhibit M-5 shall be amended by deleting in its entirety the reference to Remington House (TN).

 

       d) The description of Required Title Option Properties attached to the PSA as Exhibit M-7 shall be amended by deleting the reference to Canterbury Court (but not

  

Page 6

  

deleting the reference to Canterbury Gardens).

 

       e) The Modification Schedule attached to the PSA as Exhibit O-1 shall be amended by deleting paragraph A.(6) in its entirety and replacing such paragraph in its entirety with the following:

“(6) Each loan comprising the Assumed Real Property Loans to have a new term of at least (i) five years from and after August 1, 2010 or (ii) three years from and after August 1, 2010 with two one-year extension options and except as set forth on Exhibit O-10, such extension options shall not be subject to any extension fees, financial covenants or other conditions to extension (other than no continuing event of default).”

 

       f) The Blackstone Venture LLC Agreement attached to the PSA as Exhibit T shall be amended by deleting such exhibit in its entirety and substituting therefor Exhibit T attached to this Amendment.

3. Loan Modifications.  Stayton acknowledges and agrees that Purchaser has not waived its rights under the PSA (including, without limitation those rights set forth in Section 7.1(i) and 8.6) with respect to any modifications to the Existing Real Property Loans and Existing Personal Property Loans required by the Modification Schedule which are not specifically satisfied in the modification documents or term sheets attached the Reorganization Plan or any modification or supplement to the Reorganization Plan.

4. Except as modified by this Amendment, the PSA remains in full force and effect and is unmodified.

5. This Amendment may be executed in two or more identical counterparts which, when taken together, shall constitute one and the same instrument.  Facsimile or .pdf copies of signature pages shall be deemed originals for the purposes of the creation of a fully executed, delivered and enforceable counterpart of this Amendment.

[Signature pages follow]

  

Page 7

  

IN WITNESS WHEREOF, the parties have executed this Amendment as of July 13, 2010.

	
Purchaser:

	
Sellers:

	
  BRE/SW PORTFOLIO LLC,

    a Delaware limited liability company

 

    By:   /s/ David Roth

    Name:   David Roth

   Title:      Managing Director

	
On Behalf of Stayton:

    STAYTON SW ASSISTED LIVING, L.L.C.

    an Oregon limited liability company

 

        By: /s/Clyde A. Hamstreet

      Clyde A. Hamstreet, in his capacity

       as Chief Restructuring Officer for

      Debtor and the Receivership Entities

 

    By: /s/ Michael A. Grassmueck

           Michael A. Grassmueck, in his

           capacity as Receiver for Debtor and

           the Receivership Entities

 

  

  

  

Exhibit A-2

Allocated Purchase Price

 

The valuations described herein shall only be used for the purposes set forth herein and shall not be used for purposes of determining a Rollover Investor's capital account in Rollover Member.  Each Rollover Investor's capital account in Rollover Member will be equal to the amount that the Rollover Investor would have received if the Rollover Investor had chosen to receive cash for its claim against Seller rather than contributing its Contributed Interest and receiving a membership interest in the Rollover Member.

 

 

 

  

  

  

Exhibit T

Blackstone Venture LLC Agreement

(see attached)cphi10qex101063010.htm

 

EMPLOYMENT AGREEMENT

This EMPLOYMENT AGREEMENT is made and entered into as of April 28, 2010 (the “Agreement”), by and between CHINA PHARMA HOLDINGS, INC., a Delaware corporation (the “Company”), having its principal place of business at 2nd floor, No. 17 Jinpan Rd. Haikou, Hainan, People’s Republic of China 570216, and Frank Waung (“Employee”), with United States Social Insurance No. XXX XX XXXX (Collectively the “Parties”).

WITNESSETH:

WHEREAS, the Company is engaged in the business of develop, manufacture, and market specialty pharmaceutical products in China (the “business”); and

WHEREAS, Employee has represented that he has the experience, background and expertise necessary to enable his to be the Company’s Chief Financial Officer; and

WHEREAS, based on such representation, and the Company’s reasonable due diligence, the Company wishes to employ Employee as its Chief Financial Officer, and Employee wishes to be so employed, in each case, upon the terms hereinafter set forth;

NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants and agreements herein contained, and other good and valuable consideration, the parties agree as follows:

	
1.  

	
DEFINITIONS. As used herein, the following terms shall have the following meanings:

 “Affiliate” means any Person controlling, controlled by or under common control with the Company.

 

 “Board” means the Board of Directors of the Company.

 “Cause” means (i) conviction of any crime whether or not committed in the course of his employment by the Company; (ii) Employee’s refusal to carry out instructions of the Chief Executive Officer; or (iii) the breach of any representation, warranty or agreement between Employee and the Company.

 

 “Date of Termination” means (a) in the case of a termination for which a Notice of Termination (as hereinafter defined in section 5.3) is required, 30 days from the date of actual receipt of such Notice of Termination or, if later, the date specified therein, as the case may be, and (b) in all other cases, the actual date on which the Employee’s employment terminates during the Term of Employment(as hereinafter defined in section 3) (it being understood that nothing contained in this definition of “Date of Termination” shall affect any of the cure rights provided to the Employee or the Company in this Agreement).

 

 “Disability” means Employee’s inability to render for a period of three consecutive months, services hereunder due to his physical or mental incapacity.

 

 

  

  

  

 

 “Effective Date” means April 28, 2010.

 

 “Person(s)” means any individual or entity of any kind or nature, including any other person as defined in section 3(a)(9) of the Securities Exchange Act of 1934, and as used in Section 13(d) and 14(d) thereof.

 

 “Prospective Customer” shall mean any Person which has either (a) entered into a nondisclosure agreement with the Company or any company subsidiary or Affiliate or (b) has within the preceding 12 months received a currently pending and not rejected written proposal in reasonable detail from the Company or any of the Company’s subsidiary or Affiliate.

 

	
2.  

	
EMPLOYMENT.

2.1  Agreement to Employ. Effective as of the Effective Date, the Company hereby agrees to employ Employee, and Employee hereby agrees to serve, subject to the provisions of this Agreement, as an officer and Employee of the Company.

 

2.2  Duties and Schedule. Employee shall serve as the Company’s full time Chief Financial Officer and shall have such responsibilities as designated by the Company’s Chief Executive Officer or the Board, or the Audit Committee thereof, as circumstances may require.

 

	
3.  

	
TERM OF EMPLOYMENT. Unless Employee’s employment shall sooner terminate pursuant to section 5, the Company shall employ Employee for a term commencing on the Effective Date and ending on the first anniversary thereof (the “Term”) . The term shall automatically renew for an additional year unless either party provides notice to the other that the Term shall not continue within 60 days prior to the end of the prior Term. The period during which Employee is employed pursuant to this Agreement shall be referred to as the “Term” or the “Term of Employment”.

	
4.  

	
COMPENSATION.

 

4.1  Salary. Employee’s salary during the Term shall be USD$150,000.00 per year (the “Salary”), payable in monthly payments and in US Dollars. All applicable withholding taxes shall be deducted from such payments. The Board will review Employee’s Salary at least once per year and may, in its discretion, increase or decrease the Salary in accordance with the Company’s compensation policies. A discretionary bonus, if any, may be paid each year as determined solely by the Board.

 

 4.2  Options. Subject to the Company’s 2009 Stock Option Plan and the stock option agreement to be entered into between the Company and the Employee, the Company will grant 200,000 options to the Employee at the exercise price equal to the closing price of the Effective Date (USD3.47). The options shall be vested in one year anniversary from the Effective Date, i.e., April 28, 2010. If this agreement is terminated either by the Company or by the Employee before April 28, 2011, the number of options that shall become immediately exercisable shall be calculated as following: 200,000 options (in the event a Qualified Financing, as the term defined in the Option Grant Agreement, is consummated by the time set forth therein) or 150,000 options (in the event a Qualified Financing, as the term defined in the Option Grant Agreement, is not consummated by the time set forth therein) times the following fraction: (i) the number of months from the Effective Date to the termination date (including the last month the Employee is employed even though it may not be a full calendar month) divided by (ii) twelve (12).

 

  

  

  

 

4.3  Vacation. Employee shall be entitled to fifteen (15) days of paid vacation per year taken at such times so as to not materially impede his duties hereunder. Employee shall be entitled to a pro rata number of days of paid vacation during the period beginning on the Effective Date through the end of the first fiscal year. Vacation days that are not taken may not be carried over into future years. Illness days shall be consistent with the Company’s standard policies and applicable US law. Employee should be entitled to standard US federal government holidays in addition to vacation or illness days.

 

4.4  Business Expenses. Employee shall be reimbursed by the Company for all ordinary and necessary expenses incurred by Employee in the performance of his duties hereunder on behalf of the Company, not to exceed $500 per month without the prior written approval of the Company.

 

	
5.  

	
TERMINATION.

5.1  Termination Due to Death or Disability

 

5.1.1  Death. This Agreement shall terminate immediately upon the death of the Employee. Upon Employee’s death, Employee’s estate or Employee’s legal representative, as the case may be, shall be entitled to Employee’s accrued and unpaid Salary and vacation as of the date of Employee’s death, plus all other compensation and benefits that were vested through the date of Employee’s death.

 

5.1.2  Disability. In the event of Employee’s Disability, this agreement shall terminate and Employee shall be entitled to (a) accrued and unpaid vacation through the first date that a Disability is determined; and (b) all other compensation and benefits that were vested through the first date that a Disability has been determined.

 

5.2  Termination. Both the Company and the Employee may terminate the employment hereunder by delivery of written notice to the other party at least thirty (30) days prior to termination date or with a shorter notice period if agreed upon by the Parties provided, however, that in the event of a breach of this agreement by the Employee or an event which would constitute “Cause”, the Company may immediately terminate this agreement upon written notice with no waiting period. If this agreement is terminated by the Company without “Cause”, granted stock options will become exercisable immediately. Upon the effective date of termination under this section 5.2, Employee shall be entitled to (a) accrued and unpaid vacation through such effective date; and (b) all other compensation and benefits that were vested through such effective date.

 

 5.3  Notice of Termination. Any termination of the Employment by the Company or the Employee shall be communicated by a notice in accordance with section 8.4 of this agreement (the “Notice of Termination”).

 

  

  

  

 

 5.4  Payment. The Employee shall not be entitled to severance payments upon any termination provided in section 5 herein.

 

	
6.  

	
EMPLOYEE’S REPRESENTATION. The Employee represents and warrants to the Company that: (a) he is subject to no contractual, fiduciary or other obligation which may affect the performance of his duties under this agreement; (b) he has terminated, in accordance with their terms, any contractual obligation which may affect his performance under this agreement; and (c) his employment with the Company will not require him to use or disclose proprietary or confidential information of any other person or entity.

 

	
7.  

	
NON-COMPETITION; NON-DISCLOSURE; INVENTIONS.

	
7.1  

	
Trade Secrets. Employee acknowledges that his employment position with the Company is one of trust and confidence. Employee further understands and acknowledges that, during the course of Employee’s employment with the Company. Employee will be entrusted with access to certain confidential information, specialized knowledge and trade secrets which belong to the Company, or its subsidiaries, including, but not limited to, their methods of operation and developing customer base, its manner of cultivating customer relations, its practices and preferences, current and future market strategies, formulas, patterns, patents, devices, secret inventions, processes, compilations of information, records, and customer lists, all of which are regularly used in the operation of their business and which Employee acknowledges have been acquired, learned and developed by them only through the expenditure of substantial sums of money, time and effort, which are not readily ascertainable, and which are discoverable only with substantial effort, and which thus are the confidential and the exclusive Property of the Company and its subsidiaries(hereinafter “Trade Secrets”) . Employee covenants and agrees to use his best efforts and utmost diligence to protect those Trade Secrets from disclosure to third parties. Employee further acknowledges that, absent the protections afforded the Company and its subsidiaries in section 7, Employee would not be entrusted with any of such Trade Secrets. Accordingly, Employee agrees and covenants (which agreement and covenant shall survive the termination of this agreement regardless of the reason) as follows:

 

 

 

  

  

  

	
7.1.1  

	
Employee will at no time take any action or make any statement that will disparage or discredit the Company, any of its subsidiaries or their products or services;

	
7.1.2  

	
During the period of Employee’s with the Company and for 60 months immediately following the Termination of such employment. Employee will not disclose or reveal to any person, firm or corporation other than in connection with the business of the Company and its subsidiaries or as may be required by law, any Trade Secrets used or useable by the Company or any of its subsidiaries, divisions or Affiliates (collectively the “Companies”) in connection with their respective businesses, known to Employee as a result of his employment by the Company, or other relationship with the Companies, and which is not otherwise publicly available. Employee further agrees that during the Term of this Agreement and at all times thereafter, he will keep confidential and not disclose or reveal to any person, firm or corporation other than in connection with the business of the Companies or as may be required by applicable law, any information received by him during the course of his employment with regard to the financial, business, or other affairs of the Companies, their respective officers, directors, customers or suppliers which is not publicly available;

	
7.1.3  

	
Upon the Termination of Employee’s employment with the Company, Employee will return to the Company all documents, customer lists, customer information, product samples, presentation materials, drawing specifications, equipment and other materials relating to the business of any of the Companies, which Employee hereby acknowledges are the sole and exclusive property of the Companies or any one of them. Nothing to his personal entitlements and obligations, his rolodex, his personal correspondence files; and any additional personal property;

 

	
7.1.4  

	
During the Term of the Agreement and, for a period of three(3) months immediately following the Termination of the Employee’s employment with the Company, Employee will not : compete, or participate as a shareholder, director, officer, partner(limited or general ), trustee, holder of a beneficial interest, employee, agent of or representative in any business competing directly with the Companies without the prior written consent of the Company, which may be withheld in the Company’s sole discretion; provided, however, that nothing contained herein shall be construed to limit or prevent the purchase or beneficial ownership by Employee of less than five percent of any security registered under Section 12 or 15 of the Securities Exchange Act of 1934;

	
7.1.5  

	
During the Term of the Agreement and, for a period of eighteen (18) months immediately following the Termination of the Employee’s employment with the Company, Employee will not:

	
7.1.5.1  

	
solicit or accept competing business from any customer of any of the Companies or any person or entity known by Employee to be or have been, during the preceding 18 months, a customer or Prospective Customer of any of the Companies without the prior written consent of the Company;

 

 

  

  

  

 

 

	
7.1.5.2  

	
encourage, request or advise any such customer or Prospective Customer of any of the Companies to withdraw or cancel any of their business from or with any of the Companies; or

 

	
7.1.6  

	
Employee will not during the period of her employment with the Company and, subject to the provisions hereof for a period of eighteen (18) months immediately following the Termination of Employee’s employment with the Company.

	
7.1.6.1  

	
conspire with any person employed by any of the Company with respect to any of the matters covered by this Section 7;

 

	
7.1.6.2  

	
encourage, induce or solicit any person employed by any of the Companies to facilitate Employee’s violation of the covenants in this Section 7;

 

	
7.1.6.3  

	
assist any entity to solicit the employment of any Employee of any of the Companies; or

 

	
7.1.6.4  

	
employ or hire any Employee of any of the Companies, or solicit or induce any such person to join the Employee as a partner, investor, coventurer, or otherwise encourage or induce them to Terminate their employment with any of the Companies.

 

	
7.2  

	
Employee expressly acknowledges that all of the provisions of this Section 7 of this Agreement have been bargained for and Employee’s agreement hereto is an integral part of the consideration to be rendered by the Employee which justifies the rate and extent of the compensation provided for hereunder.

	
7.3  

	
Employee acknowledges and agrees that a violation of any one of the covenants contained in this Section 7 shall cause irreparable injury to the Company, that the remedy at law for such a violation would be inadequate and that the Company shall thus be entitled to temporary injunctive relief to enforce that covenant until such time that a court of competent jurisdiction either (a) grants or denies permanent injunctive relief or (b) awards other equitable remedy(s) as it sees fit.

	
7.4  

	
Successors.

	
7.4.1  

	
Employee. This Agreement is personal to Employee and, without the prior express written consent of the Company, shall not be assignable by Employee, except that Employee’s rights to receive any compensation or benefits under this Agreement may be transferred or disposed of pursuant to testamentary disposition, interstate, succession or a qualified domestic relations order or in connection with a Disability. This Agreement shall inure to the benefit of and be enforceable by Employee’s estate, heirs, beneficiaries, and/or legal representatives.

	
7.4.2  

	
The Company. This Agreement shall inure to the benefit of and be binding upon the Company and its successors and assigns.

 

	
7.5  

	
Inventions and Patents. The Company shall be entitled to the sole benefit and exclusive ownership of any inventions or improvements in products, processes, or other things that may be made or discovered by Employee while he is in the service of the Company, and all patents for the same. During the Term, Employee shall do all acts necessary or required by the Company to give effect to this Section and, following the Term. Employee shall do all acts reasonably necessary or required by the Company to give effect to this Section. In all cases, the Company shall pay all costs and fees associated with such acts by Employee.

 

 

 

  

  

  

 

	
8  

	
MISCELLANEOUS.

 

	
8.1  

	
Indemnification. The company and each of its subsidiaries shall, to the maximum extent provided under applicable law, indemnify and hold Employee harmless from and against any expenses, including reasonable attorney’s fees, judgments, fines, settlements and other legally permissible amounts (“Losses”), incurred in connection with any proceeding arising out of, or related to, Employee’s employment by the Company, other than any such Losses incurred as a result of Employee’s negligence or willful misconduct.  The Company shall, or shall cause a subsidiary thereof to, advance to Employee any expenses, including attorney’s fees and cots of settlement, incurred in defending any such proceeding to the maximum extent permitted by applicable law.  Such costs and expenses incurred by Employee in defense of any such proceeding shall be paid by the Company or applicable subsidiary in advance of the final disposition of such proceeding promptly up on receipt by the Company of (a) written request for payment; (b) appropriate documentation evidencing the incurrence, amount and nature of the costs and expenses for which payment is being sought; and (c) an undertaking adequate under applicable law made by or on behalf of Employee to repay the amounts so advanced if it shall ultimately be determined pursuant to any non-appeal able judgment or settlement that Employee is not entitled to the indemnified by the Company or any subsidiary thereof, the Company will provide Employee with coverage under all director’s and officer’s liability insurance policies which it has in effect during the Term, with no deductible to Employee.

 

	
8.2  

	
Applicable Law. Except as may be otherwise provided herein, this Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, applied without reference to principles of conflict of laws.

 

	
8.3  

	
Amendments. This Agreement may not be amended or modified otherwise than by a written Agreement executed by the Parties hereto or their respective successors or legal representatives.

	
8.4  

	
Notices. All notices and other communications hereunder shall be in writing and shall be given by hand-delivery to the other party or by registered or certified mail, return receipt requested, postage prepaid, addressed as follows:

If to the Employee

Frank Waung

XXXXXXXXXXXX

XXXXXXXXXXXX

 

 

  

  

  

If to the Company:

For Company:

Zhilin Li

President & Chief Executive Officer

China Pharma Holdings, Inc.

17 Jinpan Road, 2nd Floor

Haikou, Hainan Province, PR China

Tel: 86-898-66811730

Fax: 86-898-66819024

Or to such other address as either party shall have furnished to the other in writing in accordance herewith. Notices and communications shall be effective when actually received by the addressee.

 

	
8.5  

	
Withholding. The Company may withhold from any amounts payable under the Agreement, such federal, state and local income, unemployment, social security and similar employment related taxes and similar employment related withholdings as shall be required to be withheld pursuant to any applicable law or regulation.

 

	
8.6  

	
Severability. The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement, and any such provision which is not valid or enforceable in whole shall be enforced to the maximum extent permitted by law.

 

	
8.7  

	
Captions. The captions of this Agreement are not part of the provisions and shall have no force or effect.

	
8.8  

	
Entire Agreement. This Agreement contains the entire Agreement among the Parties concerning the subject matter hereof and supersedes all prior Agreements, understandings, discussions, negotiations and undertakings, whether written or oral, between the Parties with respect thereto.

	
8.9  

	
Survivorship. The respective rights and obligations of the Parties hereunder shall survive any Termination of this Agreement or the Employee’s employment hereunder to the extent necessary to the intended preservation of such rights and obligations.

	
8.10  

	
Waiver. Either Party’s failure to enforce any provision or provisions of this Agreement shall not in any way be construed as a waiver of any such provision or provisions, or prevent that party thereafter from enforcing each and every other provision of this Agreement.

 

 

  

  

  

 

 

	
8.11  

	
Joint Efforts/ Counterparts. Preparation of this Agreement shall be deemed to be the joint effort of the Parties hereto and shall not be construed more severely against any party. This Agreement may be signed in two or more counterparts, each of which shall be deemed an original and all of which together shall constitute one and the same instrument.

	
8.12  

	
Representation by Counsel. Each party hereby represents that it has had the opportunity to be represented by legal counsel of its choice in connection with the negotiation and execution of this Agreement.

 

	
8.13  

	
 Entire Agreement. This Agreement and the option agreement by and between the same Parties as those to this Agreement constitute the entire understanding of the Parties regarding the rights and obligations by and between the Parties associated with the Employee’s employment during the Term and supersedes all previous discussion and negotiation on the subject. For the purpose of clarification, the Amendment to the Employment Agreement dated as of September 28, 2009, the Employment Agreement dated as of April 28, 2009 and the option agreement dated as of October 13, 2009 govern the rights and obligations by and between the Parties associated with the Employee’s employment during the term from April 28, 2009 through April 27, 2010 only.

IN WITNESS WHEREOF, the Parties have executed this Agreement as of the day and year first above written.                                                                           

	EMPLOYEE 	CHINA PHARMA HOLDINGS, INC. 
	 	 
	
By:   /s/ Frank Waung

	
By:   /s/ Zhilin Li                                          

	
Frank Waung

	
Zhilin Li                            

	
(Date)

	
(Date)

	
 

	
President & Chief Executive Officer

	 	 
	 	 
	 	 
	  	  
	
Signature

 

China Pharma Holdings, Inc.

 

President & CEO

 

Zhilin Li

 

	
Signature

 

Frank Waung

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00177-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00177-of-00352.parquet"}]]